This study found that the levels of A beta 40 and P-tau181 in cerebrospinal fluid can predict the occurrence of atypical AD phenotypes. However, the sensitivity was poor, indicating the need for further research and validation.
Objectives. This study aimed at testing whether CSF levels of amyloid beta 42 (A beta 42), A beta 40, total tau and phosphorylated tau (P-tau181) individually contribute to the identification of atypical phenotypes among a retrospective cohort of probable AD patients diagnosed by means of the ratio between A beta 42 and A beta 40 (A beta 42/40). Methods. The retrospective study cohort comprised 50 probable AD patients diagnosed by means of the ratio between A beta 42 and A beta 40 (A beta 42/40) and for whom total tau and P-tau181 values were also available. Patients were clinically classified as typical, amnestic-predominant AD (N=39; 16 males; mean age: 73.4 +/- 7.6 years; mean disease duration: 27.4 +/- 24.7 months) or atypical phenotypes (N=11; 6 males; mean age: 70.2 +/- 6.5 years; mean disease duration: 35.5 +/- 24.9 months) - i.e., posterior cortical atrophy (PCA; N=4), logopenic-variant primary progressive aphasia (lvPPA; N=4) and behavioural-variant AD (bvAD; N=3). A logistic regression allowed to predict the occurrence of atypical vs. typical phenotypes based on age, sex, and A beta 42, A beta 40, total tau and P-tau181 levels. Results. Atypical and typical AD patients were comparable for A beta 42/40 values. Only A beta 40 and P-tau181 levels positively (p=.015) and negatively (p=.019) predicted the occurrence of atypical AD phenotypes, respectively. Classification precision was of 86%, yielding excellent specificity (94.9%), but poor sensitivity (54.5%). Conclusions. The present study delivers promising, albeit preliminary, evidence on the utility of A beta 40 and P-tau181 CSF biomarkers in differentiating atypical from typical A beta 42/40-confirmed AD phenotypes, prompting further research and confirmation on larger cohorts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据